Saniona AB (STO:SANION) reported on Wednesday net profit of SEK15.3m, or diluted EPS of SEK0.68, for the third quarter of 2018, from July 2018 to September 2018.
This was an improvement over a net loss of SEK13.4m, or SEK0.61 per diluted share, in Q3 2017.
Net revenues for the quarter were SEK44.6m, as compared with SEK4.2m in Q3 2017.
During the quarter, Saniona received a research milestone payment of SEK41.8m, as a result of the candidate selection by Boehringer Ingelheim. Under the agreement, Saniona may receive up to EUR90m in milestone payments. In addition, Saniona is entitled to tiered royalties on net sales of any potential products commercialised by Boehringer Ingelheim as a result of this collaboration.
As of 14 November 2018, Saniona has received a total of EUR9m under the collaboration.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
(EUR1.00=SEK10.27)
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials